Document Detail

Mesenchymal stromal cells to treat cardiovascular disease: strategies to improve survival and therapeutic results.
MedLine Citation:
PMID:  20228724     Owner:  NLM     Status:  MEDLINE    
Following myocardial infarction, damage due to ischemia potentially leads to heart failure. Stem cell transplantation has emerged as a potential treatment to repair the injured heart, due to the inherent characteristics of stem cells such as self-renewal, unlimited capacity for proliferation and ability to differentiate to various cell lineages. Most promising results have been reported thus far on mesenchymal stem cells (MSC). Following transplantation in the heart, stem cells are expected to 1) reduce the damage; 2) activate the endogenous regenerative potential of the heart; and 3) participate in the regeneration of the tissue. Until now, the results of intervention with stem cells in animals were promising, but clinical studies have failed to live up to those expectations. Current problems limiting the efficacy of cellular therapy are: 1) limited knowledge on the time and mode of administration; 2) loss of homing receptors on culture-expanded cells as a consequence of the culture conditions; 3) massive cell death in the transplanted graft in the damaged heart, due to the hostile environment, 4) lack of knowledge on MSC behaviour in the heart. Since generally only 1-5% of delivered cells were found to actually engraft within the infarct zone, there is an urgent need for improvement. In animal models, strategies to precondition MSC before transplantation to survive in the damaged heart were applied successfully. These include exposure of cells to physical treatments (hypoxia and heat shock), pharmacological agents, "priming" of cells with growth factors, and genetic modification by over-expression of anti-apoptotic proteins, growth factors or pro-survival genes. To develop the strategy with maximal engraftment, survival and function of cells in the heart is the ultimate challenge for years to come.
W A Noort; D Feye; F Van Den Akker; D Stecher; S A J Chamuleau; J P G Sluijter; P A Doevendans
Related Documents :
23103664 - Murine and human pluripotent stem cell-derived cardiac bodies form contractile myocardi...
24140644 - Hepatocytes contribute to immune regulation in the liver by activation of the notch sig...
23642054 - Human progenitor cells for bone engineering applications.
16168894 - The role of stem cells in the response to myocardial and vascular wall injury.
14734524 - The activation status of neuroantigen-specific t cells in the target organ determines t...
9551974 - Identification of an inhibitory mhc receptor on alloreactive rat natural killer cells.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Panminerva medica     Volume:  52     ISSN:  1827-1898     ISO Abbreviation:  Panminerva Med     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-03-15     Completed Date:  2010-07-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0421110     Medline TA:  Panminerva Med     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  27-40     Citation Subset:  IM    
Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiovascular Diseases / therapy*
Cell Differentiation
Cell Transplantation
Mesenchymal Stem Cells / cytology*
Regenerative Medicine
Stromal Cells / cytology*
Survival Rate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Autophagy and the ubiquitin-proteasome system in cardiac dysfunction.
Next Document:  Novel treatment strategy with direct renin inhibition against heart failure.